Figure 3From: Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled studyEffect of six month therapy with trimetazidine or placebo on wall motion score index (WMSI). A significant improvement in WMSI was detected in patients receiving trimetazidine while no change was noted in patients allocated to standard care and placeboBack to article page